Healthcare >> CEO Interviews >> April 4, 2016
David Pernock serves as Fibrocell Science Inc.’s Chairman of the board and Chief Executive Officer. Previously, he held various positions at GlaxoSmithKline, or GSK, most notably serving as Senior Vice President of Pharmaceuticals, Vaccines, Biologics, Oncology, Acute Care and HIV Divisions. Prior to that, Mr. Pernock served as President of Reliant Pharmaceuticals when Reliant was acquired by GSK. He was President of SmithKline Beecham—Puerto Rico prior to the GSK merger. Furthermore, Mr. Pernock served as a director of Martek Biosciences Corporation and is currently a member of the board of directors for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX). Mr. Pernock holds a B.S. in business administration from Arizona State University. Profile
Mr. Pernock: Our focus on the patient drives everything we do, and as a result, our path forward is clear: to
